XML 53 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Pay vs Performance Disclosure - USD ($)
 12 Months Ended
Dec. 31, 2022
Dec. 31, 2021
Dec. 31, 2020
Pay vs Performance Disclosure [Table]      
Pay vs Performance [Table Text Block]
Pay Versus Performance Disclosure
In
accordance with rules adopted by the SEC pursuant to the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010, we provide the following disclosure regarding executive compensation paid to our principal executive officer (“PEO”) and
Non-PEO
NEOs and Company financial performance for each of the fiscal years ended December 31, 2020, 2021 and 2022. The HR and Compensation Committee did not consider the pay versus performance disclosure below in making its pay decisions for any of the years shown.
 
                                                                 
Year
   
Summary
Compensation
Table Total for
Kåre Schultz
($) (1)
     
Compensation
Actually Paid
to Kåre
Schultz
($)
(1)(2)(3)
     
Average
Summary
Compensation
Table Total
for
Non-PEO

NEOs
($) (1)
     
Average
Compensation
Actually Paid
to
Non-PEO

NEOs
($)
(1)(2)(3)
    
Value of Initial
Fixed $100
Investment based
on: (4)
     
Net
Income
($
Millions)
    
Non-GAAP

Operating
Profit
($ Millions)
(5)
  
 
TSR
($)
    
Peer Group
TSR
($)
  
  (a)
   
(b)
     
(c)
     
(d)
     
(e)
    
(f)
    
(g)
     
(h)
    
(i)
  
2022
      15,529,138        17,214,057        3,977,166        4,426,020       93.06       123.43        (2,406 )      4,139  
2021
      14,681,772        7,570,056        3,740,840        3,075,466       81.73       129.31        456       4,401  
2020
      15,724,518        10,866,321        3,997,258        3,783,167       98.47       114.32        (4,099 )      4,388  
(1)
Kåre Schultz was our PEO for each year presented. The individuals comprising the
Non-PEO
NEOs for each year presented are listed below.
 
         
     
 
2020
 
   
 
2021
 
   
 
2022
 
     
 
Eli Kalif
   
 
Eli Kalif
   
 
Eli Kalif
     
 
Dr. Hafrun Fridriksdottir
   
 
Dr. Sven Dethlefs
   
 
Dr. Sven Dethlefs
     
 
Brendan O’Grady
   
 
Eric Drapé
   
 
Mark Sabag
     
 
Eric Drapé
   
 
Mark Sabag
   
 
Eric Drapé
(2)
The amounts shown for Compensation Actually Paid have been calculated in accordance with Item 402(v) of Regulation
S-K
and do not reflect compensation actually earned, realized, or received by the Company’s NEOs. These amounts reflect the Summary Compensation Table Total with certain adjustments as described in footnote 3 below.
(3)
Compensation Actually Paid reflects the exclusions and inclusions of certain amounts for the PEO and the
Non-PEO
NEOs as set forth below. Equity values are calculated in accordance with FASB ASC Topic 718. Amounts in the Exclusion of Stock Awards column are the totals from the Stock Awards columns set forth in the Summary Compensation Table.
 
                                 
         
Year
   
Summary Compensation
Table Total for Kåre
Schultz
($)
     
Exclusion of Stock
Awards and Option
Awards for Kåre Schultz
($)
    
Inclusion of Equity
Values for Kåre Schultz
($)
     
Compensation Actually
Paid to Kåre Schultz
($)
  
         
2022
      15,529,138        (9,999,990 )      11,684,909        17,214,057  
         
2021
      14,681,772        (9,999,994 )      2,888,278        7,570,056  
         
2020
      15,724,518        (9,999,970 )      5,141,773        10,866,321  
 
                                 
         
Year
   
Average Summary
Compensation Table
Total for Non-PEO NEOs

($)
     
Average Exclusion of
Stock Awards and
Option Awards for
Non-PEO
NEOs
($)
     
Average Inclusion of
Equity Values for
Non-PEO
NEOs
($)
     
Average Compensation
Actually Paid to
Non-PEO
NEOs
($)
  
         
2022
      3,977,166        (2,074,994 )       2,523,848        4,426,020  
         
2021
      3,740,840        (1,949,990 )       1,284,616        3,075,466  
         
2020
      3,997,258        (2,012,487 )       1,798,396        3,783,167  
 
The amounts in the Inclusion of Equity Values in the tables above are derived from the amounts set forth in the following tables:
 
                                                         
Year
  
Year-End Fair

Value of
Equity Awards
Granted
During Year
That Remained
Unvested as of
Last Day of
Year for Kåre
Schultz
($)
    
Change in Fair
Value from
Last Day of
Prior Year to
Last Day of
Year of
Unvested
Equity Awards
for
Kåre Schultz
($)
    
Vesting-Date

Fair Value of
Equity Awards
Granted
During Year
that Vested
During Year
for
Kåre Schultz
($)
    
Change in Fair
Value from
Last Day of
Prior Year to
Vesting Date
of Unvested
Equity Awards
that Vested
During Year
for
Kåre Schultz
($)
    
Fair Value at
Last Day of
Prior Year of
Equity Awards
Forfeited
During Year
for
Kåre Schultz
($)
    
Value of
Dividends or
Other
Earnings Paid
on Equity
Awards Not
Otherwise
Included for
Kåre Schultz
($)
    
Total -
Inclusion of
Equity Values
for Kåre
Schultz
($)
  
2022
     12,225,190       (546,605 )      0       6,324       0       0       11,684,909  
2021
     7,614,065       (5,298,346 )      0       572,559       0       0       2,888,278  
2020
     8,077,067       (2,209,566 )      0       (725,728 )      0       0       5,141,773  
 
                                                         
Year
  
Average Year-
End Fair Value
of Equity
Awards
Granted
During Year
That Remained
Unvested as of
Last Day of
Year for
Non-PEO

NEOs
($)
    
Average
Change in Fair
Value from
Last Day of
Prior Year to
Last Day of
Year of
Unvested
Equity
Awards for
Non-PEO

NEOs
($)
    
Average
Vesting-Date

Fair Value of
Equity Awards
Granted
During Year
that Vested
During Year
for
Non-PEO

NEOs
($)
    
Average
Change in Fair
Value from
Last Day of
Prior Year to
Vesting Date
of Unvested
Equity Awards
that Vested
During Year
for
Non-PEO

NEOs
($)
    
Average Fair
Value at Last
Day of Prior
Year of Equity
Awards
Forfeited
During Year
for
Non-PEO

NEOs
($)
    
Average Value
of Dividends
or Other
Earnings Paid
on Equity
Awards Not
Otherwise
Included for
Non-PEO

NEOs
($)
    
Total - Average

Inclusion of
Equity Values
for
Non-PEO

NEOs
($)
  
2022
     2,536,721       9,389       0       (22,262 )      0       0       2,523,848  
2021
     1,484,735       (409,621 )      0       209,502       0       0       1,284,616  
2020
     1,680,018       36,926       0       81,452       0       0       1,798,396  
(4)
The Peer Group TSR set forth in this table utilizes the Dow Jones U.S. Select Pharmaceuticals Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation
S-K
included in our Annual Report for the year ended December 31, 2022. The comparison assumes $100 was invested for the period starting December 31, 2019, through the end of the listed year in the Company and in the Dow Jones U.S. Select Pharmaceuticals Index, respectively. Historical stock performance is not necessarily indicative of future stock performance.
(5)
We determined
Non-GAAP
Operating Profit to be the most important financial performance measure used to link Company performance to Compensation Actually Paid to our PEO and
Non-PEO
NEOs in 2022. For a description of how
Non-GAAP
Operating Profit is determined, please see “Executive Compensation—Compensation Discussion and Analysis—IV. Components of Our Compensation Program—Long-Term Incentive Equity-Based Compensation” above. This performance measure may not have been the most important financial performance measure for years 2021 and 2020 and we may determine a different financial performance measure to be the most important financial performance measure in future years.
   
Company Selected Measure Name Non-GAAP Operating Profit    
Named Executive Officers, Footnote [Text Block]
 
         
     
 
2020
 
   
 
2021
 
   
 
2022
 
     
 
Eli Kalif
   
 
Eli Kalif
   
 
Eli Kalif
     
 
Dr. Hafrun Fridriksdottir
   
 
Dr. Sven Dethlefs
   
 
Dr. Sven Dethlefs
     
 
Brendan O’Grady
   
 
Eric Drapé
   
 
Mark Sabag
     
 
Eric Drapé
   
 
Mark Sabag
   
 
Eric Drapé
    
Peer Group Issuers, Footnote [Text Block] The Peer Group TSR set forth in this table utilizes the Dow Jones U.S. Select Pharmaceuticals Index, which we also utilize in the stock performance graph required by Item 201(e) of Regulation
S-K
included in our Annual Report for the year ended December 31, 2022. The comparison assumes $100 was invested for the period starting December 31, 2019, through the end of the listed year in the Company and in the Dow Jones U.S. Select Pharmaceuticals Index, respectively. Historical stock performance is not necessarily indicative of future stock performance. 		   
PEO Total Compensation Amount $ 15,529,138 $ 14,681,772 $ 15,724,518
PEO Actually Paid Compensation Amount $ 17,214,057 7,570,056 10,866,321
Adjustment To PEO Compensation, Footnote [Text Block]
                                 
         
Year
   
Summary Compensation
Table Total for Kåre
Schultz
($)
     
Exclusion of Stock
Awards and Option
Awards for Kåre Schultz
($)
    
Inclusion of Equity
Values for Kåre Schultz
($)
     
Compensation Actually
Paid to Kåre Schultz
($)
  
         
2022
      15,529,138        (9,999,990 )      11,684,909        17,214,057  
         
2021
      14,681,772        (9,999,994 )      2,888,278        7,570,056  
         
2020
      15,724,518        (9,999,970 )      5,141,773        10,866,321  
    
Non-PEO NEO Average Total Compensation Amount $ 3,977,166 3,740,840 3,997,258
Non-PEO NEO Average Compensation Actually Paid Amount $ 4,426,020 3,075,466 3,783,167
Adjustment to Non-PEO NEO Compensation Footnote [Text Block]
                                 
         
Year
   
Average Summary
Compensation Table
Total for Non-PEO NEOs

($)
     
Average Exclusion of
Stock Awards and
Option Awards for
Non-PEO
NEOs
($)
     
Average Inclusion of
Equity Values for
Non-PEO
NEOs
($)
     
Average Compensation
Actually Paid to
Non-PEO
NEOs
($)
  
         
2022
      3,977,166        (2,074,994 )       2,523,848        4,426,020  
         
2021
      3,740,840        (1,949,990 )       1,284,616        3,075,466  
         
2020
      3,997,258        (2,012,487 )       1,798,396        3,783,167  
    
Compensation Actually Paid vs. Total Shareholder Return [Text Block]
Description of Relationship Between PEO and
Non-PEO
NEO Compensation Actually Paid and Company Total Shareholder Return (“TSR”)
 
 
 
The following graph sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our
Non-PEO
NEOs, and the Company’s cumulative TSR over the three most recently completed fiscal years.
 
LOGO 		   
Compensation Actually Paid vs. Net Income [Text Block]
Description of Relationship Between PEO and
Non-PEO
NEO Compensation Actually Paid and Net Income
The following graph sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our
Non-PEO
NEOs, and our Net Income during the three most recently completed fiscal years.
 
LOGO 		   
Compensation Actually Paid vs. Company Selected Measure [Text Block]
Description of Relationship Between PEO and
Non-PEO
NEO Compensation Actually Paid and
Non-GAAP
Operating Profit
 
 
The following graph sets forth the relationship between Compensation Actually Paid to our PEO, the average of Compensation Actually Paid to our
Non-PEO
NEOs, and our
Non-GAAP
Operating Profit during the three most recently completed fiscal years.
 
LOGO 		   
Total Shareholder Return Vs Peer Group [Text Block]
Description of Relationship Between Company TSR and Peer Group TSR
The following graph compares our cumulative TSR over the three most recently completed fiscal years to that of the Dow Jones U.S. Select Pharmaceuticals Index over the same period.
 
LOGO 		   
Tabular List [Table Text Block]
Tabular List of Most Important Financial Performance Measures
The following table presents the financial performance measures that the Company considers to have been the most important in linking Compensation Actually Paid to our PEO and other NEOs for fiscal year 2022 to Company performance. The performance measures included in this table are not ranked by relative importance.
 
 
Most Important Performance Measures
 
Non-GAAP
Operating Profit
Net Revenue
Relative TSR
Non-GAAP
Earnings Per Share
Free Cash Flow
    
Total Shareholder Return Amount $ 93.06 81.73 98.47
Peer Group Total Shareholder Return Amount 123.43 129.31 114.32
Net Income (Loss) $ (2,406,000,000) $ 456,000,000 $ (4,099,000,000)
Company Selected Measure Amount 4,139,000,000 4,401,000,000 4,388,000,000
PEO Name Kåre Schultz    
Measure [Axis]: 1      
Pay vs Performance Disclosure [Table]      
Measure Name Non-GAAP Operating Profit    
Non-GAAP Measure Description [Text Block] We determined
Non-GAAP
Operating Profit to be the most important financial performance measure used to link Company performance to Compensation Actually Paid to our PEO and
Non-PEO
NEOs in 2022. For a description of how
Non-GAAP
Operating Profit is determined, please see “Executive Compensation—Compensation Discussion and Analysis—IV. Components of Our Compensation Program—Long-Term Incentive Equity-Based Compensation” above. This performance measure may not have been the most important financial performance measure for years 2021 and 2020 and we may determine a different financial performance measure to be the most important financial performance measure in future years.
   
Measure [Axis]: 2      
Pay vs Performance Disclosure [Table]      
Measure Name Net Revenue    
Measure [Axis]: 3      
Pay vs Performance Disclosure [Table]      
Measure Name Relative TSR    
Measure [Axis]: 4      
Pay vs Performance Disclosure [Table]      
Measure Name Non-GAAP Earnings Per Share    
Measure [Axis]: 5      
Pay vs Performance Disclosure [Table]      
Measure Name Free Cash Flow    
PEO [Member] | Exclusion of Stock Awards and Option Awards [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount $ (9,999,990) $ (9,999,994) $ (9,999,970)
PEO [Member] | Inclusion of Equity Values [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 11,684,909 2,888,278 5,141,773
PEO [Member] | YearEnd Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 12,225,190 7,614,065 8,077,067
PEO [Member] | Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount (546,605) (5,298,346) (2,209,566)
PEO [Member] | VestingDate Fair Value of Equity Awards Granted During Year that Vested During Year [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 0 0 0
PEO [Member] | Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 6,324 572,559 (725,728)
PEO [Member] | Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 0 0 0
PEO [Member] | Value of Dividends or Other Earnings Paid on Equity Awards Not Otherwise Included [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 0 0 0
Non-PEO NEO [Member] | Exclusion of Stock Awards and Option Awards [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount (2,074,994) (1,949,990) (2,012,487)
Non-PEO NEO [Member] | Inclusion of Equity Values [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 2,523,848 1,284,616 1,798,396
Non-PEO NEO [Member] | YearEnd Fair Value of Equity Awards Granted During Year That Remained Unvested as of Last Day of Year [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 2,536,721 1,484,735 1,680,018
Non-PEO NEO [Member] | Change in Fair Value from Last Day of Prior Year to Last Day of Year of Unvested Equity Awards [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 9,389 (409,621) 36,926
Non-PEO NEO [Member] | VestingDate Fair Value of Equity Awards Granted During Year that Vested During Year [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 0 0 0
Non-PEO NEO [Member] | Change in Fair Value from Last Day of Prior Year to Vesting Date of Unvested Equity Awards that Vested During Year [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount (22,262) 209,502 81,452
Non-PEO NEO [Member] | Fair Value at Last Day of Prior Year of Equity Awards Forfeited During Year [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount 0 0 0
Non-PEO NEO [Member] | Value of Dividends or Other Earnings Paid on Equity Awards Not Otherwise Included [Member]      
Pay vs Performance Disclosure [Table]      
Adjustment to Compensation Amount $ 0 $ 0 $ 0